CN110914433A - 编码crispr相关蛋白质的核酸及其用途 - Google Patents

编码crispr相关蛋白质的核酸及其用途 Download PDF

Info

Publication number
CN110914433A
CN110914433A CN201880020941.8A CN201880020941A CN110914433A CN 110914433 A CN110914433 A CN 110914433A CN 201880020941 A CN201880020941 A CN 201880020941A CN 110914433 A CN110914433 A CN 110914433A
Authority
CN
China
Prior art keywords
sequence
nucleic acid
utr
variant
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880020941.8A
Other languages
English (en)
Chinese (zh)
Inventor
F·切维斯图内森
M·波尼什
T·施莱克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curevac SE
Original Assignee
Curevac AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curevac AG filed Critical Curevac AG
Publication of CN110914433A publication Critical patent/CN110914433A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880020941.8A 2017-03-24 2018-03-23 编码crispr相关蛋白质的核酸及其用途 Pending CN110914433A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/057110 2017-03-24
EP2017057110 2017-03-24
EP2017076775 2017-10-19
EPPCT/EP2017/076775 2017-10-19
PCT/EP2018/057552 WO2018172556A1 (en) 2017-03-24 2018-03-23 Nucleic acids encoding crispr-associated proteins and uses thereof

Publications (1)

Publication Number Publication Date
CN110914433A true CN110914433A (zh) 2020-03-24

Family

ID=61801946

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880020941.8A Pending CN110914433A (zh) 2017-03-24 2018-03-23 编码crispr相关蛋白质的核酸及其用途

Country Status (11)

Country Link
US (3) US11739335B2 (https=)
EP (1) EP3601576A1 (https=)
JP (2) JP2020513824A (https=)
KR (1) KR102842382B1 (https=)
CN (1) CN110914433A (https=)
AU (1) AU2018240515B2 (https=)
BR (1) BR112019015244A2 (https=)
CA (1) CA3050616A1 (https=)
MX (1) MX2019011215A (https=)
SG (2) SG10202110491PA (https=)
WO (1) WO2018172556A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111328343A (zh) * 2017-08-22 2020-06-23 萨克生物研究学院 Rna靶向方法和组合物

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
MX2013010911A (es) 2011-03-23 2015-03-03 Pioneer Hi Bred Int Metodos para producir un locus de rasgo transgenico complejo.
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
RU2658490C2 (ru) 2012-03-27 2018-06-21 Кьюрвак Аг Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
RU2718988C2 (ru) 2013-02-22 2020-04-15 Куревак Аг Комбинация противораковой рнк-вакцины и ингибитора пути pd-1 и ее применение
BR112016001192A2 (pt) 2013-08-21 2017-08-29 Curevac Ag Vacina contra a raiva
BR112016003361A2 (pt) 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
AU2014310935B2 (en) 2013-08-21 2019-11-21 CureVac SE Combination vaccine
CA3109801C (en) 2013-08-22 2024-01-09 Andrew Cigan Plant genome modification using guide rna/cas endonuclease systems and methods of use
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
WO2015135558A1 (en) 2014-03-12 2015-09-17 Curevac Gmbh Combination of vaccination and ox40 agonists
CN108064129A (zh) 2014-09-12 2018-05-22 纳幕尔杜邦公司 玉米和大豆中复合性状基因座的位点特异性整合位点的产生和使用方法
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
CA2963820A1 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
DE202015010000U1 (de) 2014-12-12 2023-07-03 CureVac SE Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
DK3294885T3 (da) 2015-05-08 2020-08-10 Curevac Real Estate Gmbh Fremgangsmåde til at fremstille rna
AU2016261358B2 (en) 2015-05-11 2021-09-16 Editas Medicine, Inc. Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells
PL4108769T3 (pl) 2015-05-29 2024-02-05 CureVac Manufacturing GmbH Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym
EP3307887A1 (en) 2015-06-09 2018-04-18 Editas Medicine, Inc. Crispr/cas-related methods and compositions for improving transplantation
AU2016326711B2 (en) 2015-09-24 2022-11-03 Editas Medicine, Inc. Use of exonucleases to improve CRISPR/Cas-mediated genome editing
US11413346B2 (en) 2015-11-09 2022-08-16 Curevac Ag Rotavirus vaccines
EP3701963A1 (en) 2015-12-22 2020-09-02 CureVac AG Method for producing rna molecule compositions
US11723967B2 (en) 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
EP3433363A1 (en) 2016-03-25 2019-01-30 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
WO2017180694A1 (en) 2016-04-13 2017-10-19 Editas Medicine, Inc. Cas9 fusion molecules gene editing systems, and methods of use thereof
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
EP4631970A3 (en) 2016-05-04 2026-01-07 CureVac SE Nucleic acid molecules and uses thereof
US10337051B2 (en) 2016-06-16 2019-07-02 The Regents Of The University Of California Methods and compositions for detecting a target RNA
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
CA3038960A1 (en) 2016-09-30 2018-04-05 The Regents Of The University Of California Rna-guided nucleic acid modifying enzymes and methods of use thereof
JP7306696B2 (ja) 2016-09-30 2023-07-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｒｎａ誘導型核酸修飾酵素及びその使用方法
US11279923B2 (en) 2016-11-28 2022-03-22 Curevac Ag Method for purifying RNA
WO2018119010A1 (en) 2016-12-19 2018-06-28 Editas Medicine, Inc. Assessing nuclease cleavage
EP3558355A2 (en) 2016-12-23 2019-10-30 CureVac AG Henipavirus vaccine
EP3558356A2 (en) 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
WO2018115525A1 (en) 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
EP3565907B1 (en) 2017-01-06 2022-05-04 Editas Medicine, Inc. Methods of assessing nuclease cleavage
US10876101B2 (en) 2017-03-28 2020-12-29 Locanabio, Inc. CRISPR-associated (Cas) protein
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
WO2018211038A1 (en) 2017-05-17 2018-11-22 Curevac Ag Method for determining at least one quality parameter of an rna sample
WO2018227114A1 (en) 2017-06-09 2018-12-13 Editas Medicine, Inc. Engineered cas9 nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
MX2019015505A (es) 2017-06-30 2020-07-28 Inscripta Inc Metodos, modulos, instrumentos y sistemas de procesamiento de celulas automatizados.
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
US11970720B2 (en) 2017-08-22 2024-04-30 Salk Institute For Biological Studies RNA targeting methods and compositions
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
CN111630173A (zh) * 2017-10-19 2020-09-04 库瑞瓦格股份公司 新型人工核酸分子
WO2019089804A1 (en) 2017-11-01 2019-05-09 The Regents Of The University Of California Casy compositions and methods of use
JP2021503278A (ja) 2017-11-01 2021-02-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ＣａｓＺ組成物及び使用方法
WO2019089808A1 (en) 2017-11-01 2019-05-09 The Regents Of The University Of California Class 2 crispr/cas compositions and methods of use
EP3707271A1 (en) 2017-11-08 2020-09-16 CureVac AG Rna sequence adaptation
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
EP3728634A1 (en) 2017-12-21 2020-10-28 CureVac AG Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
KR20200124702A (ko) * 2018-02-23 2020-11-03 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 신규한 cas9 오르소로그
WO2019204210A1 (en) * 2018-04-16 2019-10-24 Georgia Tech Research Corporation Mrna driven expression of rna editors for treatment of pathologies
CA3091558A1 (en) 2018-04-17 2019-10-24 Curevac Ag Novel rsv rna molecules and compositions for vaccination
US10526598B2 (en) 2018-04-24 2020-01-07 Inscripta, Inc. Methods for identifying T-cell receptor antigens
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
BR112020025601A8 (pt) 2018-06-28 2022-07-05 Tesla Automation GmbH Biorreator para a transcrição in vitro de rna
EP3823633A4 (en) 2018-06-29 2023-05-03 Editas Medicine, Inc. SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
AU2019292919A1 (en) 2018-06-30 2021-03-11 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
WO2020023529A1 (en) * 2018-07-24 2020-01-30 The Regents Of The University Of California Rna-guided nucleic acid modifying enzymes and methods of use thereof
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
RU2706298C1 (ru) * 2018-09-14 2019-11-15 Закрытое Акционерное Общество "Биокад" НУКЛЕАЗА PaCas9
EP3640329A1 (en) * 2018-10-18 2020-04-22 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Gene editing based cancer treatment
US20210395709A1 (en) * 2018-10-18 2021-12-23 Chan Zuckerberg Biohub, Inc. Methods and compositions involving thermostable cas9 protein variants
AU2019365100B2 (en) * 2018-10-22 2025-10-09 University Of Rochester Genome editing by directed non-homologous DNA insertion using a retroviral integrase-Cas9 fusion protein
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
KR102929968B1 (ko) * 2018-11-12 2026-02-25 아프타리온 바이오테크 아게 Cxcl8 결합 핵산
CA3121191A1 (en) * 2018-11-28 2020-06-04 Crispr Therapeutics Ag Optimized mrna encoding cas9 for use in lnps
US12365888B2 (en) 2018-12-14 2025-07-22 Pioneer Hi-Bred International, Inc. CRISPR-Cas systems for genome editing
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
US12492425B2 (en) 2018-12-21 2025-12-09 CureVac SE Methods for RNA analysis
ES2970169T3 (es) * 2018-12-27 2024-05-27 Lifeedit Therapeutics Inc Polipéptidos útiles para edición génica y métodos de uso
WO2020142739A1 (en) * 2019-01-04 2020-07-09 Mammoth Biosciences, Inc. COMPOSITIONS AND METHODS FOR DETECTING MODIFIED NUCLEIC ACIDS AND AMPLIFYING ssDNA
US20220133908A1 (en) 2019-02-08 2022-05-05 Curevac Ag Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
US20220298494A1 (en) * 2019-02-14 2022-09-22 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
CA3130789A1 (en) 2019-03-07 2020-09-10 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof
WO2020186059A2 (en) * 2019-03-12 2020-09-17 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
CN113631713A (zh) 2019-03-25 2021-11-09 因思科瑞普特公司 酵母中的同时多重基因组编辑
WO2020223553A2 (en) * 2019-04-30 2020-11-05 Emendobio Inc. Novel omni crispr nucleases
AU2020288623A1 (en) 2019-06-06 2022-01-06 Inscripta, Inc. Curing for recursive nucleic acid-guided cell editing
PH12021553076A1 (en) 2019-06-07 2023-08-14 Scribe Therapeutics Inc Engineered casx systems
WO2021011504A1 (en) * 2019-07-12 2021-01-21 Duke University Nanoparticle systems for targeted delivery of crispr/cas13 and methods of using same
KR20220062289A (ko) * 2019-08-12 2022-05-16 라이프에디트 테라퓨틱스, 인크. Rna-가이드된 뉴클레아제 및 그의 활성 단편 및 변이체 및 사용 방법
US11203762B2 (en) 2019-11-19 2021-12-21 Inscripta, Inc. Methods for increasing observed editing in bacteria
KR102776469B1 (ko) * 2019-12-10 2025-03-05 인스크립타 인코포레이티드 신규 mad 뉴클레아제
US20230075913A1 (en) * 2019-12-16 2023-03-09 BASF Agricultural Solutions Seed US LLC Codon-optimized cas9 endonuclease encoding polynucleotide
EP4069851A4 (en) 2019-12-18 2023-11-22 Inscripta, Inc. Cascade/dcas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
KR20220121246A (ko) 2019-12-20 2022-08-31 큐어백 아게 핵산 전달용 신규한 지질 나노입자
AU2021213705A1 (en) 2020-01-27 2022-06-16 Inscripta, Inc. Electroporation modules and instrumentation
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
WO2021168799A1 (en) * 2020-02-28 2021-09-02 Huigene Therapeutics Co., Ltd. Type vi-e and type vi-f crispr-cas system and uses thereof
GB2608292B (en) 2020-03-31 2024-02-14 Metagenomi Inc Class II, type II CRISPR systems
WO2021211598A1 (en) * 2020-04-14 2021-10-21 University Of Massachusetts Dcas13-mediated therapeutic rna base editing for in vivo gene therapy
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
TW202208626A (zh) * 2020-04-24 2022-03-01 美商生命編輯公司 Rna引導核酸酶及其活性片段與變體，以及使用方法
EP4165177A4 (en) * 2020-05-08 2024-08-28 Metagenomi, Inc. ENZYMES WITH RUVC DOMAINS
US11946077B2 (en) 2020-06-04 2024-04-02 Emendobio Inc. OMNI-59, 61, 67, 76, 79, 80, 81, and 82 CRISPR nucleases
WO2022060749A1 (en) 2020-09-15 2022-03-24 Inscripta, Inc. Crispr editing to embed nucleic acid landing pads into genomes of live cells
WO2022098681A2 (en) * 2020-11-03 2022-05-12 Caspr Biotech Corporation Novel class 2 crispr-cas rna-guided endonucleases
CA3197406A1 (en) * 2020-11-05 2022-05-12 Chengzu LONG Enhancement of predictable and template-free gene editing by the association of cas with dna polymerase
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
AU2021392719B2 (en) 2020-12-03 2025-08-14 Scribe Therapeutics Inc. Engineered class 2 type v crispr systems
US20240156946A1 (en) 2020-12-22 2024-05-16 CureVac SE Rna vaccine against sars-cov-2 variants
AU2021415461A1 (en) * 2021-01-04 2023-08-17 Inscripta, Inc. Mad nucleases
AU2022205595A1 (en) * 2021-01-05 2023-08-17 Dxlab Inc. Methods for detection of nucleic acids
US20240376451A1 (en) 2021-01-07 2024-11-14 Inscripta, Inc. Mad nucleases
KR20230142740A (ko) 2021-02-08 2023-10-11 에멘도바이오 인코포레이티드 Omni-103 crispr 뉴클레아제
US12091688B2 (en) 2021-02-08 2024-09-17 Emendobio Inc. OMNI-103 CRISPR nuclease
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
WO2022232638A2 (en) * 2021-04-30 2022-11-03 Metagenomi, Inc. Enzymes with ruvc domains
WO2022272294A1 (en) * 2021-06-23 2022-12-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for efficient retron recruitment to dna breaks
JP2024532784A (ja) * 2021-08-13 2024-09-10 エメンドバイオ・インコーポレイテッド 新規なｏｍｎｉ－１１５、１２４、１２７、１４４～１４９、１５９、２１８、２３７、２４８、２５１～２５３及び２５９ｃｒｉｓｐｒヌクレアーゼ
CA3225082A1 (en) 2021-08-27 2023-03-02 Brian C. Thomas Enzymes with ruvc domains
MX2024002726A (es) 2021-09-03 2024-03-20 CureVac SE Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos.
MX2024006257A (es) 2021-11-24 2024-07-29 Metagenomi Inc Sistemas de endonucleasas.
US20250043260A1 (en) * 2021-12-01 2025-02-06 Emendobio Inc. Engineered High Activity Omni-79 Nuclease Variants
JP2024546841A (ja) * 2021-12-17 2024-12-26 ビーム セラピューティクス インク． 新規ｃｒｉｓｐｒ酵素、方法、システム、及びそれらの使用
CN119317713A (zh) * 2022-01-24 2025-01-14 生命编辑制药股份有限公司 Rna引导核酸酶、其活性片段与变体，及使用方法
JP2025505148A (ja) * 2022-02-02 2025-02-21 インスクリプタ， インコーポレイテッド 核酸ガイド型ニッカーゼ融合タンパク質
CN114807104B (zh) * 2022-04-11 2024-02-20 西南大学 肺炎克雷伯菌噬菌体裂解酶及其制备方法和应用
WO2024042165A2 (en) * 2022-08-26 2024-02-29 UCB Biopharma SRL Novel rna-guided nucleases and nucleic acid targeting systems comprising such rna-guided nucleases
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
JP2026501585A (ja) * 2022-12-28 2026-01-16 エメンドバイオ・インコーポレイテッド Ｏｍｎｉ－３３５ ｃｒｉｓｐｒヌクレアーゼ
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
CN121285578A (zh) * 2023-04-07 2026-01-06 总医院公司 点击安装型基因组编辑
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
CN121752723A (zh) * 2023-08-31 2026-03-27 正基基因科技有限公司 编码crispr相关蛋白的核酸及其应用
WO2025132815A1 (en) * 2023-12-20 2025-06-26 Novozymes A/S Novel cas nucleases and polynucleotides encoding the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2866945A1 (en) * 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
WO2015006747A2 (en) * 2013-07-11 2015-01-15 Moderna Therapeutics, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use.
EP2831240A2 (en) * 2012-03-27 2015-02-04 Curevac GmbH Artificial nucleic acid molecules comprising a 5'top utr

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
ATE490267T1 (de) 2001-06-05 2010-12-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen
EP2390331B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
WO2009086558A1 (en) 2008-01-02 2009-07-09 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
EP2176408B9 (en) 2008-01-31 2015-11-11 Curevac GmbH NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS
US20110054009A1 (en) 2008-02-28 2011-03-03 The Ohio State University Research Foundation MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Prostate Related Disorders
AU2009238175C1 (en) 2008-04-15 2023-11-30 Arbutus Biopharma Corporation Novel lipid formulations for nucleic acid delivery
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
CN104119242B (zh) 2008-10-09 2017-07-07 泰米拉制药公司 改善的氨基脂质和递送核酸的方法
WO2010048536A2 (en) 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Processes for preparing lipids
ES2646630T3 (es) 2008-11-07 2017-12-14 Massachusetts Institute Of Technology Lipidoides aminoalcohólicos y usos de los mismos
HUE037082T2 (hu) 2008-11-10 2018-08-28 Arbutus Biopharma Corp Új lipidek és készítmények terápiás hatóanyagok szállítására
WO2010087791A1 (en) 2009-01-27 2010-08-05 Utc Power Corporation Distributively cooled, integrated water-gas shift reactor and vaporizer
EP3243504A1 (en) 2009-01-29 2017-11-15 Arbutus Biopharma Corporation Improved lipid formulation
KR20180094137A (ko) 2009-05-05 2018-08-22 알닐람 파마슈티칼스 인코포레이티드 지질 조성물
MX342785B (es) 2009-06-10 2016-10-12 Alnylam Pharmaceuticals Inc Formulacion mejorada de lipido.
BR112012002291A2 (pt) 2009-07-31 2016-11-29 Ethris Gmbh "polirribonucleotídeo com uma sequência que codifica uma proteína ou fragmento de proteína, implante, e, processo para a seleção de sequências de nucleotídeos"
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
CN104959087B (zh) 2010-04-09 2017-08-15 帕西拉制药有限公司 用于配制大直径合成膜囊泡的方法
SG186085A1 (en) 2010-06-03 2013-01-30 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
HUE026646T2 (en) 2010-07-06 2016-07-28 Glaxosmithkline Biologicals Sa Preferred liposomes containing lipids of PKA value for delivery of RNA
EP2590625B1 (en) 2010-07-06 2017-09-20 GlaxoSmithKline Biologicals SA Cationic oil-in-water emulsions
CA2801523C (en) 2010-07-30 2021-08-03 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
ES2727583T3 (es) 2010-08-31 2019-10-17 Glaxosmithkline Biologicals Sa Lípidos adecuados para la administración liposómica de ARN que codifica proteínas
RS63890B1 (sr) 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
PT3970742T (pt) 2010-08-31 2022-06-27 Glaxosmithkline Biologicals Sa Lipossomas peguilados para entrega de arn codificador de imunogénio
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
US20140141070A1 (en) 2011-07-06 2014-05-22 Andrew Geall Liposomes having useful n:p ratio for delivery of rna molecules
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
SG11201405157PA (en) 2012-02-24 2014-10-30 Protiva Biotherapeutics Inc Trialkyl cationic lipids and methods of use thereof
SG10201607962RA (en) 2012-03-27 2016-11-29 Curevac Ag Artificial nucleic acid molecules
RU2658490C2 (ru) * 2012-03-27 2018-06-21 Кьюрвак Аг Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов
WO2013174409A1 (en) 2012-05-25 2013-11-28 Curevac Gmbh Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
US20140200261A1 (en) 2013-01-17 2014-07-17 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
RU2718988C2 (ru) 2013-02-22 2020-04-15 Куревак Аг Комбинация противораковой рнк-вакцины и ингибитора пути pd-1 и ее применение
MX374090B (es) 2013-03-14 2025-03-05 Caribou Biosciences Inc Composiciones y métodos de ácidos nucleicos dirigidos al ácido nucleico.
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
WO2014204724A1 (en) * 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
SG11201510747RA (en) 2013-08-21 2016-03-30 Curevac Ag Method for increasing expression of rna-encoded proteins
BR112016001192A2 (pt) 2013-08-21 2017-08-29 Curevac Ag Vacina contra a raiva
AU2014310935B2 (en) 2013-08-21 2019-11-21 CureVac SE Combination vaccine
WO2015024664A1 (en) 2013-08-21 2015-02-26 Curevac Gmbh Composition and vaccine for treating prostate cancer
BR112016003361A2 (pt) 2013-08-21 2017-11-21 Curevac Ag vacina do vírus sincicial respiratório (rsv)
DK3035955T3 (da) 2013-08-21 2019-12-02 Curevac Ag Sammensætning og vaccine til behandling af lungekræft
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
US9593077B2 (en) 2013-11-18 2017-03-14 Arcturus Therapeutics, Inc. Ionizable cationic lipid for RNA delivery
US20170173128A1 (en) 2013-12-06 2017-06-22 Moderna TX, Inc. Targeted adaptive vaccines
KR102399799B1 (ko) 2013-12-30 2022-05-18 큐어백 아게 인공 핵산 분자
SG11201604198YA (en) 2013-12-30 2016-07-28 Curevac Ag Methods for rna analysis
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
WO2015135558A1 (en) 2014-03-12 2015-09-17 Curevac Gmbh Combination of vaccination and ox40 agonists
CA2936286A1 (en) 2014-04-01 2015-10-08 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
US10837039B2 (en) 2014-06-10 2020-11-17 Curevac Real Estate Gmbh Methods and means for enhancing RNA production
SMT202200502T1 (it) 2014-06-25 2023-01-13 Acuitas Therapeutics Inc Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici
DE202015010000U1 (de) 2014-12-12 2023-07-03 CureVac SE Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
CA2962849A1 (en) 2014-12-16 2016-06-23 Curevac Ag Ebolavirus and marburgvirus vaccines
EP3233132A4 (en) 2014-12-19 2018-06-27 Modernatx, Inc. Terminal modifications of polynucleotides
KR102580696B1 (ko) 2014-12-30 2023-09-19 큐어백 에스이 신규 인공 핵산 분자
EP3283059B1 (en) 2015-04-13 2024-01-03 CureVac Manufacturing GmbH Method for producing rna compositions
SG11201707663SA (en) 2015-04-17 2017-11-29 Curevac Ag Lyophilization of rna
RU2749113C2 (ru) 2015-04-22 2021-06-04 Куревак Аг Содержащая рнк композиция для лечения опухолевых заболеваний
US20180208957A1 (en) 2015-04-30 2018-07-26 Curevac Ag Method for in vitro transcription using an immobilized restriction enzyme
ES2897823T3 (es) 2015-04-30 2022-03-02 Curevac Ag Poli(N)polimerasa inmovilizada
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
DK3294885T3 (da) 2015-05-08 2020-08-10 Curevac Real Estate Gmbh Fremgangsmåde til at fremstille rna
KR20180004820A (ko) 2015-05-15 2018-01-12 큐어백 아게 적어도 하나의 mRNA 구성의 투여를 포함하는 신규 프라임-부스트 요법
WO2016184575A1 (en) 2015-05-20 2016-11-24 Curevac Ag Dry powder composition comprising long-chain rna
EP3297682B1 (en) 2015-05-20 2021-07-14 CureVac AG Dry powder composition comprising long-chain rna
PL4108769T3 (pl) 2015-05-29 2024-02-05 CureVac Manufacturing GmbH Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym
EP4098743A1 (en) 2015-05-29 2022-12-07 CureVac AG Method for adding cap structures to rna using immobilized enzymes
US20180245074A1 (en) * 2015-06-04 2018-08-30 Protiva Biotherapeutics, Inc. Treating hepatitis b virus infection using crispr
US20180296663A1 (en) 2015-06-17 2018-10-18 Curevac Ag Vaccine composition
US20190017100A1 (en) 2015-07-01 2019-01-17 Curevac Ag Method for analysis of an rna molecule
WO2017009376A1 (en) 2015-07-13 2017-01-19 Curevac Ag Method of producing rna from circular dna and corresponding template dna
WO2017021546A1 (en) 2015-08-05 2017-02-09 Curevac Ag Epidermal mrna vaccine
DK3332019T3 (da) 2015-08-07 2020-02-17 Curevac Ag Fremgangsmåde til in vivo-produktionen af rna i en værtscelle
WO2017025447A1 (en) 2015-08-10 2017-02-16 Curevac Ag Method of increasing the replication of a circular dna molecule
CA2992801A1 (en) * 2015-08-28 2017-03-09 Curevac Ag Artificial nucleic acid molecules
ES2964690T3 (es) 2015-09-21 2024-04-09 Trilink Biotechnologies Llc Método para sintetizar ARN con caperuza 5'
US11225682B2 (en) 2015-10-12 2022-01-18 Curevac Ag Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
IL307179A (en) 2015-10-28 2023-11-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3374504B1 (en) 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
US11413346B2 (en) 2015-11-09 2022-08-16 Curevac Ag Rotavirus vaccines
US20180371392A1 (en) 2015-12-21 2018-12-27 Curevac Ag Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
EP3701963A1 (en) 2015-12-22 2020-09-02 CureVac AG Method for producing rna molecule compositions
EP3394280A1 (en) 2015-12-23 2018-10-31 CureVac AG Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
WO2017140345A1 (en) 2016-02-15 2017-08-24 Curevac Ag Method for analyzing by-products of rna in vitro transcription
US11723967B2 (en) 2016-02-17 2023-08-15 CureVac SE Zika virus vaccine
EP3423595A1 (en) 2016-03-03 2019-01-09 CureVac AG Rna analysis by total hydrolysis
US20190177714A1 (en) 2016-03-24 2019-06-13 Curevac Ag Immobilized inorganic pyrophosphatase (ppase)
EP3777881A1 (en) 2016-04-22 2021-02-17 CureVac AG Rna encoding a tumor antigen
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
EP4631970A3 (en) 2016-05-04 2026-01-07 CureVac SE Nucleic acid molecules and uses thereof
EP4233898A3 (en) 2016-05-04 2023-11-01 CureVac SE Influenza mrna vaccines
US20180126003A1 (en) 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
MA45052A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
WO2017201348A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
AU2017266932B2 (en) 2016-05-18 2023-04-20 Modernatx, Inc. Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease
US20190298657A1 (en) 2016-05-18 2019-10-03 Modernatx, Inc. Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
WO2017201347A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
MA45036A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2
EP3458104A1 (en) 2016-05-18 2019-03-27 Modernatx, Inc. Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
WO2017203008A1 (en) 2016-05-25 2017-11-30 Curevac Ag Novel biomarkers
WO2017212009A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
WO2017212008A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
WO2017212006A1 (en) 2016-06-09 2017-12-14 Curevac Ag Hybrid carriers for nucleic acid cargo
WO2017212007A1 (en) 2016-06-09 2017-12-14 Curevac Ag Cationic carriers for nucleic acid delivery
MX2019001920A (es) 2016-08-19 2019-07-01 Curevac Ag Arn la terapia contra el cancer.
BR112019008481A2 (pt) 2016-10-26 2020-03-03 Curevac Ag Vacinas de mrna de nanopartículas lipídicas
US11279923B2 (en) 2016-11-28 2022-03-22 Curevac Ag Method for purifying RNA
EP3551230A1 (en) 2016-12-08 2019-10-16 CureVac AG Rna for treatment or prophylaxis of a liver disease
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
EP3558356A2 (en) 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
WO2018115525A1 (en) 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
EP3558355A2 (en) 2016-12-23 2019-10-30 CureVac AG Henipavirus vaccine
CA3050614A1 (en) 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
WO2018211038A1 (en) 2017-05-17 2018-11-22 Curevac Ag Method for determining at least one quality parameter of an rna sample
RU2020103379A (ru) 2017-07-04 2021-08-04 Куревак Аг Новые молекулы нуклеиновых кислот
US11602557B2 (en) 2017-08-22 2023-03-14 Cure Vac SE Bunyavirales vaccine
AR113154A1 (es) * 2017-09-29 2020-01-29 Intellia Therapeutics Inc Polinucleótidos, composiciones y métodos para edición del genoma
CN111630173A (zh) 2017-10-19 2020-09-04 库瑞瓦格股份公司 新型人工核酸分子
EP3707271A1 (en) 2017-11-08 2020-09-16 CureVac AG Rna sequence adaptation
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
EP3728634A1 (en) 2017-12-21 2020-10-28 CureVac AG Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
CA3091558A1 (en) 2018-04-17 2019-10-24 Curevac Ag Novel rsv rna molecules and compositions for vaccination
WO2020002525A1 (en) 2018-06-27 2020-01-02 Curevac Ag Novel lassa virus rna molecules and compositions for vaccination
BR112020025601A8 (pt) 2018-06-28 2022-07-05 Tesla Automation GmbH Biorreator para a transcrição in vitro de rna
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
US12492425B2 (en) 2018-12-21 2025-12-09 CureVac SE Methods for RNA analysis
CA3118034A1 (en) 2018-12-21 2020-06-25 Curevac Ag Rna for malaria vaccines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2866945A1 (en) * 2012-03-27 2013-10-03 Curevac Gmbh Artificial nucleic acid molecules comprising a 5'top utr
EP2831240A2 (en) * 2012-03-27 2015-02-04 Curevac GmbH Artificial nucleic acid molecules comprising a 5'top utr
WO2015006747A2 (en) * 2013-07-11 2015-01-15 Moderna Therapeutics, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111328343A (zh) * 2017-08-22 2020-06-23 萨克生物研究学院 Rna靶向方法和组合物
CN111328343B (zh) * 2017-08-22 2023-11-28 萨克生物研究学院 Rna靶向方法和组合物

Also Published As

Publication number Publication date
JP2024038121A (ja) 2024-03-19
CA3050616A1 (en) 2018-09-27
KR102842382B1 (ko) 2025-08-04
US12371699B2 (en) 2025-07-29
EP3601576A1 (en) 2020-02-05
SG10202110491PA (en) 2021-11-29
MX2019011215A (es) 2020-02-12
JP2020513824A (ja) 2020-05-21
RU2019132890A3 (https=) 2021-07-14
WO2018172556A1 (en) 2018-09-27
US20230332163A1 (en) 2023-10-19
US20210403925A1 (en) 2021-12-30
SG11201906297QA (en) 2019-10-30
RU2019132890A (ru) 2021-04-26
BR112019015244A2 (pt) 2020-04-14
US11739335B2 (en) 2023-08-29
AU2018240515B2 (en) 2024-07-25
KR20190133699A (ko) 2019-12-03
US20250304976A1 (en) 2025-10-02
AU2018240515A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
US12371699B2 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
US12161711B2 (en) Lassa virus vaccine
US20230158126A1 (en) Rna for treatment or prophylaxis of a liver disease
WO2020002525A1 (en) Novel lassa virus rna molecules and compositions for vaccination
US20240102065A1 (en) Method of reducing the immunostimulatory properties of in vitro transcribed rna
CN114502204A (zh) 具有降低的免疫刺激性质的rna组合和组合物
CN113453707A (zh) 用于疟疾疫苗的rna
KR20140137455A (ko) 인공 핵산 분자
WO2022200575A1 (en) Immunogenic compositions
WO2023006999A2 (en) Mrnas for treatment or prophylaxis of liver diseases
KR20230028860A (ko) 세포질에서 자가 전사가 가능하고 cDdRp mRNA를 제공하는 RNA/DNA 시스템
KR20220055399A (ko) 세포질에서 자가 전사가 가능한 mRNA를 제공하는 RNA/DNA 시스템
KR20230127070A (ko) 세포질에서 자가 전사가 가능하고 발현억제 rna를 제공하는 rna/dna 시스템
KR20230127069A (ko) 세포질에서 자가 전사가 가능한 mRNA를 제공하는 RNA/DNA 시스템
HK40050012A (en) Rna for treatment or prophylaxis of a liver disease
KR20220067468A (ko) 세포질에서 자가 전사가 가능하고 발현억제 rna를 제공하는 rna/dna 시스템

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination